Skip to content

Azenta AZTA AFS Securities

AFS Securities at other companies

Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO

Other financials

Income statement

See full
Revenue$144.8M+1.0%
Gross profit$62.0M-1.2%
Operating income-$165.8M-811%
Net income-$160.8M-237%
EPS (diluted)-$3.49-236%

Balance sheet

See full
Cash & equivalents$125.2M
Total debt$55.7M
Total equity$1.6B-8.3%
Total assets$1.9B

Cash flow

See full
Operating cash flow$13.5M-6.2%
CapEx$7.4M-0.1%
Free cash flow$6.1M-12.7%

Valuation

See full
Market cap$1.1B-16.3%
Enterprise value$1.03B
P/S1.8×-0.2×

Profitability

See full
Gross margin40%-1.0pp
Operating margin-31.6%-59.7pp
Net margin-29.1%-80.7pp
FCF margin8.6%

Returns & leverage

See full
Return on equity-10.7%-22.4pp
Debt / equity
Current ratio2.8×

Where this comes from

Reported directly by Azenta in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss.

The official record: Azenta’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Azenta's afs securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Azenta's AFS securities?
Azenta (AZTA) reported AFS securities of $324.99M in Q1 2026.
What is the long-term trend for Azenta's AFS securities?
Over 4 years (2020 to 2025), Azenta's AFS securities has grown at a 203.3% compound annual growth rate (CAGR), from $3.1M to $262.58M.
What does AFS securities mean?
Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.